Dr Reddys Laboratories Ltd Share Price Today - Dr Reddys Laboratories Ltd Stock Price Live NSE/BSE

Dr Reddys Laboratories Ltd

NSE: DRREDDY BSE: 500124

₹1232.60

(-0.25%)

Wed, 29 Apr 2026, 00:36 pm

MTF 5xInvest in Dr Reddys Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap1030.63B

PE Ratio18.17

Dividend0.65

Health Technology

Pharmaceuticals: Major

24.5K

Dr Reddys Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
113075.15
Net Profit
5725.20
P/B
2.84
Sector P/E
33.33
P/E
16.87
EV/EBITDA
10.10
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
18.53
ROCE
23.05
Debt/Equity
0.11
EPS (TTM)
66.71
Dividend Yield
0.59
Book Value
431.48
Interest Cover
28.15

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (4.7x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (7.2x coverage).
Dividends per share have been stable in the past 10 years.
Dr. Reddy's Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Dr. Reddy's Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Dr. Reddy's Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Dr. Reddy's Laboratories is expected to increase but not above the 50% threshold in 2 years time.
Dr. Reddy's Laboratories's earnings are expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).
Dr. Reddy's Laboratories's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	26.63	26.64	26.64	26.64	26.64
FII	21.14	22.34	24.69	25.32	25.75
DII	30.72	30.44	27.98	26.74	25.62
Public	21.50	20.59	20.69	21.30	21.99
Government	0	0	0	0	0

Technical Analysis

RSI

61.06

MACD

17.36

50 DMA

1274.09

200 DMA

1257.14

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1503.33	1387.23	1321.07	1271.13	1204.97	1155.03	1038.93
Fibonacci	1387.23	1342.88	1315.48	1271.13	1226.78	1199.38	1155.03
Camarilla	1286.83	1276.19	1265.54	1271.13	1244.26	1233.62	1222.97

Pivots Level: Classic

+232.20

1503.33

+116.10

1387.23

+49.93

1321.07

1271.13

Pivot Point

LTP: 1329.80

-66.17

1204.97

-116.10

1155.03

-232.20

1038.93

Moving Average

SMAEMA

Period

Value

10-EMA
1294.69
20-EMA
1274.57
30-EMA
1269.20
50-EMA
1265.23
100-EMA
1260.65
200-EMA
1256.32

Announcement Date	Purpose	Action	Ex Date
21 Jan 2026	board-meetings	Quarterly Results
10 Jun 2025	dividend	Final Dividend - Rs. - 8	10 Jul 2025
09 May 2025	agm
09 May 2025	dividend	₹8.00 Dividend /Share	10 Jul 2025
28 Sept 2024	dividend	Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share	28 Oct 2024
28 Sept 2024	split	Stock Split From Rs.5 to Rs.1	28 Oct 2024
27 Jul 2024	split	1:5 Splits of Equity Shares	28 Oct 2024
16 Jun 2024	dividend	Annual General Meeting/Dividend - Rs 40 Per Share	17 Jul 2024
07 May 2024	dividend	₹40.00 Dividend /Share	17 Jul 2024
07 May 2024	agm

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Cipla Ltd

Divis Laboratories Ltd

Lupin Ltd

Dr Reddys Laboratories Ltd About

Dr Reddys Laboratories offers a portfolio of products and services including active pharmaceutical ingredients (“APIs”), generics, branded generics, biosimilars, over the counter (“OTC”) products and pharmaceutical services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

K Satish Reddy

Employees

Contact

Website

http://www.drreddys.com

shares@drreddys.com; mail@drreddys.com

Phone

91-40-49002900

Location

8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034

Year	History
No Result Found

Client Name	Order Side	QTY	Avg Price	Date
DR REDDYS LABORATORIES LIMITED	Buy	884213	3076.83	16 Jun 2016
THE BANK OF NEW YORK MELLON REPRESENTATIVE OFFICE	Buy	1547170	1479.21	15 Jul 2010

Dr Reddys Laboratories Ltd News

Dr Reddy's Gets Health Canada Approval for Semaglutide

Dr Reddy's Laboratories receives full Health Canada approval for generic semaglutide injection, becoming first company to obtain marketing license in Canada for sales and distribution.

29 Apr 2026

companies

Dr. Reddy's Faces Delhi HC Warning Over Trademark

Delhi High Court warns Dr. Reddy's Laboratories over 'Olymviq' trademark compliance, asking for fresh undertaking on transition to 'Olymra' name for weight-loss drug following March order.

29 Apr 2026

companies

Dr. Reddy's Q4FY26 Results on May 12, 2026

Dr. Reddy's Laboratories announces Q4 and full year FY26 financial results release on May 12, 2026, followed by earnings call at 19:30 PM IST. Board meeting precedes results announcement.

25 Apr 2026

companies

Dr. Reddy's Q4FY26 Results on May 12, 2026

Dr. Reddy's Laboratories announces Q4 and full year FY26 financial results release on May 12, 2026, followed by earnings call at 19:30 PM IST. Board meeting precedes results announcement.

24 Apr 2026

companies

Dr Reddy's Awaits Canada Approval for Semaglutide

Dr Reddy's Laboratories received Drug Identification Numbers on April 22, 2026, for semaglutide injection but still awaits final Health Canada approval for market authorization.

24 Apr 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800